Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 2/20 | 0.43 |
| ▸ | ACLY | P53396 | 2/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972984 | 0.87 | AKR1C2 (0.53) | AKR1C2AKR1C1DHODHCFDKMO | |
| SCHEMBL4026660 | 0.87 | ACMSD (0.55) | DCLRE1BAKR1C2AKR1C1DHODHCFD | |
| SCHEMBL3936487 | 0.84 | DCLRE1B (0.51) | DCLRE1BAKR1C2AKR1C1DHODHCFD | |
| SCHEMBL3944255 | 0.84 | ACMSD (0.45) | AKR1C2AKR1C1DHODHCFDPTPN11 | |
| SCHEMBL2115556 | 0.84 | TSHR (0.53) | AKR1C2AKR1C1DHODHKMOANO1 | |
| SCHEMBL29646503 | 0.84 | TSHR (0.53) | AKR1C2AKR1C1DHODHKMOANO1 | |
| SCHEMBL3937100 | 0.83 | KDM4E (0.47) | CFDKMOACLYRXRARXRB | |
| SCHEMBL3947686 | 0.83 | MCL1 (0.58) | AKR1C2AKR1C1DHODHCFDKMO | |
| SCHEMBL4038391 | 0.81 | ACMSD (0.60) | DHODHCFDPTPN11ACMSD | |
| SCHEMBL4042656 | 0.81 | PTPN11 (0.51) | AKR1C2CFDACLYPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069321-A1 | CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES | BAYER SCHERING PHARMA AG (DE) | 2009-03-12 | — | — | US | claimed |
| EP-2020404-A1 | Cyanomethyl substituted N-Acyl Tryptamines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-04 | — | — | EP | claimed |
| US-20090069321-A1 | CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES | BAYER SCHERING PHARMA AG (DE) | 2009-03-12 | — | — | US | disclosed |
| EP-2020404-A1 | Cyanomethyl substituted N-Acyl Tryptamines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069321-A1 | CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES | FSHR, GNRHR, HNMT | DCLRE1B 4209/4885AKR1C2 1308/4885AKR1C1 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.